Study of the Effects of Rimonabant on Functional Recovery in Subacute Stroke Patients
Condition(s) studied
Investigational drug(s) / intervention(s)
Rimonabant: Rimonabant 5 mg administered orally as one orally disintegrating tablet (ODT) once daily for 90 consecutive days.
Placebo: Participants will receive one matching placebo orally disintegrating tablet (ODT) once daily for 90 consecutive days. The placebo contains no rimonabant.
Study summary
The main goal of this clinical trial is to assess the effect of rimonabantim on the functional independence in adults who have recently experienced a stroke. The study will enroll 80 participants aged 18 to 75 years who had an stroke 30 to 90 days before enrolment and who have difficulties performing daily activities.
Participants will receive either rimonabant (5 mg) or placebo (a look-alike tablet that contains no drug) once daily for 90 days. Neither the participants nor the investigators will know which treatment is being given.The study will also help to learn about the safety of rimonabant.
Eligibility
Primary outcome measure(s)
- Barthel Index (BI) — Baseline and end of follow-up (day 135)
The BI measures the ability to perform activities of daily living. It consists on a ten-item scale that examine functions such as feeding, bathing, continence, mobility and dressing.
Trial sites (6)
| Facility | City | Region | Status |
|---|---|---|---|
| Hospital Universitario de Albacete | Albacete | Albacete | |
| Institut Guttmann | Badalona | Barcelona | |
| Jiménez Lucena S.L. (CLÍNICA I+TÚ) | Córdoba | Córdoba | |
| Hospital Los Madroños | Brunete | Madrid | |
| Hospital Clínico San Carlos (HCSC) | Madrid | Madrid | |
| Hospital Universitario La Paz | Madrid | Madrid |
More Sinfatin S.L trials in Spain
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07941479 on ClinicalTrials.gov ↗ ← All trials in Spain